Hims & Hers Health (NYSE:HIMS) Sets New 1-Year Low After Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS) shares hit a new 52-week low during mid-day trading on Wednesday after Barclays lowered their price target on the stock from $48.00 to $25.00. Barclays currently has an overweight rating on the stock. Hims & Hers Health traded as low as $13.74 and last traded at $15.4340, with a volume of 63819824 shares traded. The stock had previously closed at $15.51.

A number of other equities research analysts have also weighed in on the stock. Truist Financial reaffirmed a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday. Evercore set a $24.00 target price on Hims & Hers Health in a report on Tuesday. Leerink Partners lowered their target price on Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating for the company in a research note on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Finally, TD Cowen lowered their price target on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Reduce” and a consensus price target of $32.27.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at $6,238,497.40. This represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the sale, the insider owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. This represents a 79.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 82,963 shares of company stock worth $2,944,621. Insiders own 13.71% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Management continues to emphasize growth and is pursuing a large international expansion via a planned acquisition of Eucalyptus, which could boost scale and addressable market outside the U.S. Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans
• Neutral Sentiment: Investor interest is elevated — unusually large options volume was reported, signaling higher speculative or hedging activity that can amplify moves in either direction. Hims & Hers Health Sees Unusually Large Options Volume (NYSE:HIMS)
• Neutral Sentiment: Comparative coverage (HIMS vs. AMWL) highlights differing telehealth strategies; useful for investors evaluating sector exposure but not an immediate catalyst. HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
• Negative Sentiment: The SEC has opened an inquiry into Hims’ disclosures about compounded GLP‑1 (semaglutide) products, increasing regulatory risk and disclosure uncertainty. Hims & Hers Stock Faces Heavy Sell-Off Amid SEC Probe Into GLP-1 Disclosures
• Negative Sentiment: Novo Nordisk filed suit alleging patent infringement over compounded weight‑loss drugs; Hims withdrew its compounded semaglutide product—potential legal and liability exposure. Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans
• Negative Sentiment: The Law Offices of Frank R. Cruz announced an investor investigation into whether the board breached fiduciary duties related to these matters, which raises litigation risk and governance scrutiny. The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
• Negative Sentiment: Multiple analyst actions: Citigroup cut its price target to $13.25 and BTIG downgraded HIMS to Neutral; those notes prompted downgrades and contributed to heavy intraday selling. Citigroup Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $13.25 BTIG Research Downgrades Hims & Hers Health (NYSE:HIMS) to Neutral
• Negative Sentiment: Shares have hit new lows after the analyst activity and headlines; commentary also flagged potential near‑term pressure from a Super Bowl ad and changes to shipping cadence that could affect short‑term volumes. Hims & Hers Stock Stumbles – Cautions About Pressure Due To Super Bowl Ad, Change In Shipping Cadences
• Negative Sentiment: Overall coverage (TipRanks, Market commentary) highlights elevated reputation, partnership and liability risks from compounded‑drug scrutiny—factors that could weigh on sentiment until legal/regulatory clarity is reached. Regulatory Scrutiny of Compounded Drugs Puts Hims & Hers’ Growth, Partnerships, and Liability Risk in the Spotlight

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Quent Capital LLC purchased a new position in Hims & Hers Health during the 3rd quarter valued at about $28,000. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at $28,000. Virtus Advisers LLC purchased a new position in shares of Hims & Hers Health in the second quarter worth about $26,000. Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health during the 2nd quarter valued at approximately $29,000. Finally, Bessemer Group Inc. lifted its position in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 1.3%

The company has a quick ratio of 1.64, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The business has a 50 day moving average price of $27.02 and a 200 day moving average price of $39.43. The stock has a market cap of $3.55 billion, a PE ratio of 30.61, a P/E/G ratio of 3.38 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the prior year, the business posted $0.11 earnings per share. Hims & Hers Health’s revenue for the quarter was up 28.4% on a year-over-year basis. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to buy up to 3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.